Skip to content

Effect of Mulberry Lingzhi tea on the inhibition of elevated blood glucose and its safety: a short-term ingestion study

Effect of Mulberry Lingzhi tea on the inhibition of elevated blood glucose and its safety: Randomized, double-blind, placebo-controlled, crossover comparative study - Short-term intake study of Mulberry Lingzhi Tea

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000055353
Enrollment
30
Registered
2024-08-28
Start date
2022-11-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired glucose tolerance

Interventions

Mulberry Lingzhi tea before meals Before every meal for 2 weeks Continuous measurement using an extracorporeal continuous blood glucose meter

Sponsors

Saga University
Lead Sponsor
Kanzaki city
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Fasting blood glucose level of at least 110 mg/dL but less than 126 mg/dL or hemoglobin A1c level is between 6.1% and 6.5%.

Exclusion criteria

Exclusion criteria: (1) Those whose blood glucose and hemoglobin A1c levels correspond to diabetes (fasting blood glucose level of 126 mg/dL or higher, hemoglobin A1c of 6.5% or higher) (2) Patients who are on continuous treatment with medication (3) Consuming medicines, foods for specified health use, functional foods, or health foods that may affect the results of the study. (4) Persons with a history of serious diseases of the heart, liver, kidney, digestive organs, etc. (5) Those with anemia (hemoglobin level of 12.5 g/dl or less for men and 11.5 g/dl or less for women) (6) Those who consume excessive amounts of alcohol (more than 60 g of pure alcohol, which is 3 times the appropriate amount, e.g., more than 1.5 L of beer or more than 3 g of sake). (7) Shift workers, late-night workers, and others with an irregular rhythm of life. (8) Persons who are allergic to medicines or food (9) Pre-menopausal women (10) Persons with implanted pacemakers (11) Other subjects deemed unsuitable by the investigator. (12) Subjects who have requested discontinuation of the study (excluded at any time upon receipt of a written withdrawal of consent).

Design outcomes

Primary

MeasureTime frame
postprandial blood glucose level during the treatment period

Countries

Japan

Contacts

Public ContactMegumi Hara

Saga University Medicine

harameg@cc.saga-u.ac.jp0952342289

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026